Source published October 18, 2026: peer-reviewed open-access pilot randomized clinical trial in the Journal of Traumatic Stress.

A carefully controlled first step Twenty-five adults with PTSD received five weekly written exposure therapy sessions and were randomized to active or sham transcranial direct current stimulation during the writing period. Twenty-four participants completed all five sessions.

What changed Both groups improved significantly. Self-reported PTSD symptoms showed an earlier reduction with active tDCS, including a significant group-by-visit interaction and a between-group difference around the fourth session. At the one-month follow-up, however, active and sham groups did not differ on clinician-rated or self-reported PTSD severity. The finding is best read as a possible acceleration signal, not evidence of greater durable benefit.

Safety and limitations No serious or unexpected related adverse events were reported. Related adverse events were descriptively more common with active stimulation: 27 events versus 12, with at least one event reported by 75.0 percent and 46.2 percent of participants, respectively. Most were expected reactions to trauma processing; five events attributed to tDCS involved expected transient skin irritation or burning.

The study was small, had only a one-month follow-up and included a sample that limits generalizability. Treatment fidelity was not rated with the same rigor as a larger definitive trial.

Funding and interests The study was supported by a University of Texas San Antonio Center for Biomedical Neurosciences intramural award. Two authors reported American Psychological Association royalties for the written exposure therapy manual. The authors also disclosed AI assistance for editing and readability.

Why it matters Pairing portable stimulation with a brief evidence-based psychotherapy raises a practical question: can a safe adjunct help people improve earlier without adding a long treatment burden? Larger trials must show whether the early difference is reproducible, clinically meaningful and durable, and whether it justifies the additional adverse-effect burden.

Disclosure This is a research summary, not a treatment recommendation. Prepared with AI assistance; full publisher text and indexed records checked October 20, 2026.